Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON54892
NL-OMON54892
Not yet recruiting
Not Applicable

PRospective tumor sampling in oncology patients with solid tumors treated with Immune Modulating Agents - PRIMA

Erasmus MC, Universitair Medisch Centrum Rotterdam0 sites350 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
Erasmus MC, Universitair Medisch Centrum Rotterdam
Enrollment
350
Status
Not yet recruiting
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Observational invasive

Investigators

Eligibility Criteria

Inclusion Criteria

  • •Histological or cytological proven solid tumor
  • •Age \>\=18 years
  • •Written informed consent
  • •Performance score: WHO 0\-2 at the time of study entry
  • •Planned treatment with (intravenous) immune modulating agents for any type of
  • •cancer according to standard of care.

Exclusion Criteria

  • •Unable to draw blood for study purposes (e.g. severe anemia Hb \<5,5 mmol/L)
  • •Unable to safely obtain tumor biopsies
  • •Known human immunodeficiency virus (HIV), chronic hepatitis B or C infection

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Not Applicable
Blood sampling of oncology patients treated with monoclonal antibodiesAll malignancies that are treated with intravenous monoclonal antibodies
NL-OMON27631Erasmus Medical Center1,000
Recruiting
Not Applicable
Prospective sampling in intravenously treated oncology patients: Monoclonal AntiBodiescancermalignancy10027655
NL-OMON53070Erasmus MC, Universitair Medisch Centrum Rotterdam2,750
Completed
Not Applicable
Protocol to obtain tumor biopsies from patients with locally advanced (incurable) or metastatic cancer to improve selection for clinical trials.metastatic cancermetastatic malignancy10027476
NL-OMON40487niversitair Medisch Centrum Utrecht1,500
Recruiting
Not Applicable
Prospective observational study molecular tumor board of the Comprehensive Cancer Center Mainfranken of the University Hospital of WürzburgC00-C97Malignant neoplasms
DRKS00029051niversitätsklinikum Würzburg998
Completed
Not Applicable
An exploratory tumor biopsy-driven study to understand the relationship between biomarkers and indicators of clinical response in immunomodulatory treatment naïve unresectable stage III/IV melanoma patients receiving REGN2810 (anti-PD-1)
NL-OMON49259Regeneron Pharmaceuticals, Inc.8